课题基金 / 基金详情

HEMATOPORPHYRIN DISTRIBUTION AND PHOTOSENSITIZATION

HEMATOPORPHYRIN DISTRIBUTION AND PHOTOSENSITIZATION
血卟啉分布和光敏化
批准号:
3482209
负责人:
CHARLES Joseph GOMER
金额:
$19.3万
依托单位国家:
美国
项目类别:
财政年份:
1982
资助国家:
美国
项目状态:
已结题
起止时间:
1982-03-01 至 1994-04-30

项目摘要

项目成果

CHARLES Joseph GOMER的其他基金

相似基金

相关文献

中文摘要
翻译
本研究计划的长期目标是描述
英文摘要
The long term objectives of this research proposal are to delineate cellular and molecular mechanisms of action involved in photodynamic therapy (PDT) and to evaluate methods for enhancing the efficacy of PDT. Clinical use of PDT continues to produce promising responses, and controlled Phase II and Phase III trials of PDT using Photofrin II (dihematoporphyrin-ether) have been initiated under the sponsorship of the Lederal Division of American Cyanamid. Enthusiasm for PDT continues to grow, but information related to basic in-vitro and in-vivo mechanisms associated with PDT needs to be obtained in order to fully evaluate the clinical potential of this modality. Cellular procedures will be utilized in isolating PDT resistant tumor cell strains. These cell strains will subsequently be used for molecular, biochemical and cellular characterization studies as well as for evaluating in-vivo PDT responses. A comprehensive evaluation of PDT sensitivity of cellular components of the vasculature will be performed utilizing cloned human and bovine cells. PDT Induces the over expression of oxidative stress proteins and this property will now be exploited in order to document in-vivo PDT target sites in treated tumors. In this regard, in-situ hybridization (using cDNA's to stress protein genes) will be performed in order to document the sites and kinetics of PDT induced oxidative stress protein mRNA expression. In-vivo procedures will also be utilized to study the adjunctive use of the hypoxic cell cytotoxin (SR-4233) with PDT. Quantitative tumor and normal tissue responses will be documented as a function of drug doses, light doses and time intervals between injections and treatments. New photosensitizers with photochemical and photobiological properties which appear to be superior to Photofrin II are available for basic research, and thereforee, both Photofrin II (the porphyrin undergoing current clinical evaluation) and new photosensitizers (such as chlorins and phthalocyanines) will be investigated in this proposal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Photodynamic Therapy Affects on the Tumor Microenvironment
  • 批准号:
    7919055
  • 项目类别:
  • 资助金额:
    $18.91万
  • 财政年份:
    2009
  • 负责人:
    CHARLES Joseph GOMER
  • 依托单位:
Enhancing Photodynamic Therapy for Treating Kaposi's Sarcoma
  • 批准号:
    7268113
  • 项目类别:
  • 资助金额:
    $14.05万
  • 财政年份:
    2006
  • 负责人:
    CHARLES Joseph GOMER
  • 依托单位:
Enhancing Photodynamic Therapy for Treating Kaposi's Sarcoma
  • 批准号:
    7120420
  • 项目类别:
  • 资助金额:
    $11.57万
  • 财政年份:
    2006
  • 负责人:
    CHARLES Joseph GOMER
  • 依托单位:
Enhancing Photodynamic Therapy with COX-2 Inhibition
  • 批准号:
    6689681
  • 项目类别:
  • 资助金额:
    $33.11万
  • 财政年份:
    2003
  • 负责人:
    CHARLES Joseph GOMER
  • 依托单位:
国内基金
海外基金
超声响应型Chlorin e6/Pyrimethamine共载胶束的构建 及其作用于肿瘤及肿瘤相关巨噬细胞对乳腺癌的治疗效应研究
  • 批准号:
    81903168
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2019
  • 负责人:
    李一向
  • 依托单位: